John Libbey Eurotext

European Journal of Dermatology

MENU

A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting Volume 33, issue 1, January-February 2023

Authors
1 Global Medical Epidemiology, Pfizer Inc., 500 Arcola Road, Dock E, Collegeville PA, 19426, USA
2 Real-World Solutions, IQVIA, Emperor Boulevard, Durham, NC 27703, USA
3 Global Medical Epidemiology, Pfizer Inc., 235 E 42nd Street, New York, NY 10017, USA
4 Institute and Comprehensive Center for Inflammation Medicine, University of Luebeck, Ratzeburger Allee 160 in 23538 Luebeck, Germany
5 Radboud University Nijmegen Medical Center, Department of Dermatology, Nijmegen, The Netherlands
6 Heim Pál Children’s Hospital, Department of Dermatology, 1089 Budapest Üllői út 86, Hungary
7 Department of Dermatology, University of Nice Côte d’Azur, Nice, France
8 Division of Dermatology, Department of Medicine, Karolinska Institutet, 17176, Stockholm, Sweden
* Reprints: Yun Gu

Psoriasis is a chronic inflammatory immune- mediated skin disorder [1], often leading to a physical, emotional, and social burden, resulting in impaired quality of life [2]. Globally, psoriasis affects 125 million people, or 2-3% of the population [3]. Nearly one-third of patients develop psoriasis in childhood [4]. The worldwide prevalence of psoriasis in children is estimated at up to 1.4% [5], with a 0.5-1.0% prevalence in Europe [6].While the majority of patients with mild to moderate psoriasis [...]

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License